Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity

Diabetes, Obesity and Metabolism

Volumn 19, Issue 8, 2017, Pages 1135-1146

  Joannides, Christos N ^a   Mangiafico, Salvatore P ^a   Waters, Matthew F ^a   Lamont, Benjamin J ^a   Andrikopoulos, Sofianos ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

antidiabetic drug; dapagliflozin; glucose metabolism; insulin resistance; insulin secretion; SGLT2 inhibitor

Indexed keywords

3 HYDROXYBUTYRIC ACID; DAPAGLIFLOZIN; GLUCOSE TRANSPORTER 4; INSULIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SGLT2 PROTEIN, RAT; SLC2A4 PROTEIN, RAT; SODIUM GLUCOSE COTRANSPORTER 2;

ADIPOCYTE; ADIPOSE TISSUE; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CHRONIC GLUCOSE OVERPRODUCTION; CONTROLLED STUDY; DRUG RESPONSE; EXCRETION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOTOXICITY; HYPERGLYCEMIA; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MUSCLE; NONHUMAN; RAT; TRANSGENIC RAT; WEIGHT GAIN; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BODY WEIGHT GAIN; CELL SIZE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; GLUCOSE CLAMP TECHNIQUE; HYPERINSULINISM; METABOLISM; OBESITY; PANCREAS ISLET; PATHOLOGY; SECRETION (PROCESS); SKELETAL MUSCLE; WHITE ADIPOSE TISSUE;

ADIPOSE TISSUE, WHITE; ADIPOSITY; ANIMALS; BENZHYDRYL COMPOUNDS; CELL SIZE; GENE EXPRESSION REGULATION; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORTER TYPE 4; GLUCOSIDES; HYPERGLYCEMIA; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MALE; MEMBRANE TRANSPORT MODULATORS; MUSCLE, SKELETAL; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); RATS, TRANSGENIC; SODIUM-GLUCOSE TRANSPORTER 2; WEIGHT GAIN;

EID: 85017375505     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12923     Document Type: Article

References (45)

1. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840-846.
2. Aston-Mourney K, Proietto J, Andrikopoulos S. Investigational agents that protect pancreatic islet beta-cells from failure. Expert Opin Investig Drugs. 2005;14(10):1241-1250.
3. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068-1083.
4. Gunton JE, Cheung NW, Davis TM, Zoungas S, Colagiuri S. A new blood glucose management algorithm for type 2 diabetes: a position statement of the Australian Diabetes Society. Med J Aust. 2014;201(11):650-653.
5. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223-2233.
6. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66(5):446-456.
7. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015-2022.
8. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32(4):515-531.
9. Lamont BJ, Andrikopoulos S, Funkat A, et al. Peripheral insulin resistance develops in transgenic rats overexpressing phosphoenolpyruvate carboxykinase in the kidney. Diabetologia. 2003;46(10):1338-1347.
10. Mangiafico SP, Lim SH, Neoh S, et al. A primary defect in glucose production alone cannot induce glucose intolerance without defects in insulin secretion. J Endocrinol. 2011;210(3):335-347.
11. Rosella G, Zajac JD, Baker L, et al. Impaired glucose tolerance and increased weight gain in transgenic rats overexpressing a non-insulin-responsive phosphoenolpyruvate carboxykinase gene. Mol Endocrinol. 1995;9(10):1396-1404.
12. Kooptiwut S, Kebede M, Zraika S, et al. High glucose-induced impairment in insulin secretion is associated with reduction in islet glucokinase in a mouse model of susceptibility to islet dysfunction. J Mol Endocrinol. 2005;35(1):39-48.
13. Zraika S, Aston-Mourney K, Laybutt DR, et al. The influence of genetic background on the induction of oxidative stress and impaired insulin secretion in mouse islets. Diabetologia. 2006;49(6):1254-1263.
14. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499-508.
15. Merovci A, Mari A, Solis C, et al. Dapagliflozin lowers plasma glucose concentration and improves beta cell function. J Clin Endocrinol Metab. 2015;100(5):1927-1932.
16. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124(2):509-514.
17. Hansen HH, Jelsing J, Hansen CF, et al. The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves beta-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat. J Pharmacol Exp Ther. 2014;350(3):657-664.
18. Millar PJ, Pathak V, Moffett RC, et al. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice. Mol Cell Endocrinol. 2016;420:37-45.
19. Neschen S, Scheerer M, Seelig A, et al. Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice. Diabetes. 2015;64(1):284-290.
20. Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E. Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice. Arch Pharm Res. 2016;39(2):259-270.
21. Lamontagne J, Jalbert-Arsenault E, Pepin E, et al. Pioglitazone acutely reduces energy metabolism and insulin secretion in rats. Diabetes. 2013;62(6):2122-2129.
22. Andrikopoulos S, Blair AR, Deluca N, Fam BC, Proietto J. Evaluating the glucose tolerance test in mice. Am J Physiol Endocrinol Metab. 2008;295(6):E1323-E1332.
23. Andrikopoulos S, Fam BC, Holdsworth A, et al. Identification of ABCC8 as a contributory gene to impaired early-phase insulin secretion in NZO mice. J Endocrinol. 2016;228(1):61-73.
24. Kebede M, Favaloro J, Gunton JE, et al. Fructose-1,6-bisphosphatase overexpression in pancreatic beta-cells results in reduced insulin secretion: a new mechanism for fat-induced impairment of beta-cell function. Diabetes. 2008;57(7):1887-1895.
25. Xirouchaki CE, Mangiafico SP, Bate K, et al. Impaired glucose metabolism and exercise capacity with muscle-specific glycogen synthase 1 (gys1) deletion in adult mice. Mol Metab. 2016;5(3):221-232.
26. Mudaliar S, Henry RR, Boden G, et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther. 2014;16(3):137-144.
27. Chen L, Klein T, Leung PS. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice. Curr Mol Med. 2012;12(8):995-1004.
28. Thomas L, Grempler R, Eckhardt M, et al. Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes Obes Metab. 2012;14(1):94-96.
29. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57(6):1723-1729.
30. Ueta K, O'Brien TP, McCoy GA, et al. Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity. Am J Physiol Endocrinol Metab. 2014;306(11):E1225-E1238.
31. De Feyter HM, Lenaers E, Houten SM, et al. Increased intramyocellular lipid content but normal skeletal muscle mitochondrial oxidative capacity throughout the pathogenesis of type 2 diabetes. FASEB J. 2008;22(11):3947-3955.
32. Smith AC, Mullen KL, Junkin KA, et al. Metformin and exercise reduce muscle FAT/CD36 and lipid accumulation and blunt the progression of high-fat diet-induced hyperglycemia. Am J Physiol Endocrinol Metab. 2007;293(1):E172-E181.
33. Ndisang JF, Jadhav A. Hemin therapy suppresses inflammation and retroperitoneal adipocyte hypertrophy to improve glucose metabolism in obese rats co-morbid with insulin-resistant type-2 diabetes. Diabetes Obes Metab. 2013;15(11):1029-1039.
34. Rodriguez-Calvo R, Serrano L, Coll T, et al. Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2. Diabetes. 2008;57(8):2149-2157.
35. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes. 2003;52(3):581-587.
36. Macdonald FR, Peel JE, Jones HB, et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab. 2010;12(11):1004-1012.
37. Jurczak MJ, Lee HY, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes. 2011;60(3):890-898.
38. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941-950.
39. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217-2224.
40. Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16(5):467-477.
41. Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring). 2012;20(8):1645-1652.
42. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1730-1735.
43. Chearskul S, Delbridge E, Shulkes A, Proietto J, Kriketos A. Effect of weight loss and ketosis on postprandial cholecystokinin and free fatty acid concentrations. Am J Clin Nutr. 2008;87(5):1238-1246.
44. Sumithran P, Prendergast LA, Delbridge E, et al. Ketosis and appetite-mediating nutrients and hormones after weight loss. Eur J Clin Nutr. 2013;67(7):759-764.
45. Visinoni S, Khalid NF, Joannides CN, et al. The role of liver fructose-1,6-bisphosphatase in regulating appetite and adiposity. Diabetes. 2012;61(5):1122-1132.